Resources

The scope of the Publicly Available Specification (PAS) focuses on health-care providers who are able to prescribe medications in Canada with specific emphasis on prescribers who do not consider th

We sought to explore experiences of Indigenous ‘family members’ (participants) in an Indigenous-led alcohol harm reduction program and culturally supportive housing to identify appropriate supports

This study sought to determine if adults who received housing were more likely than a control group to show improvements in depression, psychological distress, and self-rated mental health after mo

Supervised consumption sites (SCS) are effective at preventing overdose mortality. However, their effect on public safety remains contested.

 This study describes rates of injectable Injectable extended-release buprenorphine (BUP-ER) (Sublocade®) uptake in five provinces to compare access to this novel medication across Canada.

In the wake of the syndemics of the COVID-19 pandemic and worsening overdose deaths from synthetic opioids, we examine knowledge, attitudes, and practices of harm reduction services among community

This study sought to identify strategies used by rural people who use drugs (PWUD) to reduce harms associated with unintentional fentanyl exposure.

The study aimed to explore the attitudes, knowledge, and practices of primary healthcare providers in Georgia regarding screening and management of patients with subs

This study aims to see if contamination of surfaces by illegal drugs occurs in Drug Consumption Room to investigate drug levels and possible exposure of the staff members.

The Ministry of Health requested Unity Health Toronto complete a review of the Consumption and Treatment Service (CTS) operated by the South Riverdale Community Health Centre (SRCHC) following the

Municipalities are the front-line of addressing the unregulated, toxic drug crisis but can’t solve it alone.

The purpose of this living document is to assist service providers in better understanding the needs of the transgender, gender non-conforming, and non-binary community when utilizing Syringe Servi

On June 1, 2024, Health Canada published a Regulatory Impact Analysis Statement for the proposed Controlled S

Sublingual buprenorphine is most commonly available in co-formulation with naloxone.

The Needs Based Planning (NBP) project team undertook the development of a national set of core mental health and substance use health services as a key component for application within the NBP mod

This report outlines the current state of harm reduction funding in low-, mid-, and high- income countries.

On September 21, 2023, the HIV Legal Network hosted the “Violence Against Women (VAW) Shelter Harm Reduction Roundtable” in Toronto, Ontario.